Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

Fig. 2

Identification of a galcanezumab responder. Patient’s e-diary entry data were used to compute percentage of monthly migraine and headache days during the 1-month pre-treatment period and the 3-month treatment period. Daily documentation of headache intensity, laterality, throbbing, photophobia, phonophobia, and nausea were used to distinguish between headache and migraine days. Note that the percentage of monthly migraine days (MMD) decreased by > 50% during the treatment period (from 47% before treatment to 18.6% during the 3 months of treatment)

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us